RSS

Genoscience Pharma

Clinical-stage biotech company, Genoscience Pharma, has started administering GNS561 in a Phase I/IIa trial of patients with advanced liver cancer. more

News

Genoscience Pharma has announced that initiation of a Phase Ib/IIa study of its most advanced compound, GNS561, for the treatment of patients with advanced hepatocarcinoma (HCC), has received approval from the US Food and Drug Administration (FDA). more

News